文献速递白血病造血干细胞移植与细胞治疗

维奈克拉联合阿扎胞苷作为NPM1突变急性髓系白血病分子学失败的移植桥接策略

A venetoclax and azacitidine bridge-to-transplant strategy for NPM1-mutated acute myeloid leukaemia in molecular failure.
PubMed 文献 · Br J Haematol · 2023-05-24

该回顾性分析纳入11例NPM1突变、MRD阳性、体能状态良好的急性髓系白血病患者,其中9例分子学复发、2例分子学持续。接受维奈克拉联合阿扎胞苷中位2周期(范围1-4)后,9/11(81.8%)达到CRMRD阴性,全部11例均接受HSCT。中位随访26个月,10/11存活。

要点

  • 维奈克拉联合阿扎胞苷桥接移植后,9/11(81.8%)的NPM1突变AML分子学失败患者达到CRMRD阴性。
  • 全部11例患者均成功接受HSCT,中位随访26个月时10/11存活。
  • 该方案在移植前可防止明显复发、实现深度缓解并保持患者体能。

核心结论

  • 维奈克拉联合阿扎胞苷在NPM1突变AML分子学失败患者中显示出防止明显复发、实现深度缓解和保持移植前体能的疗效与安全性。

研究设计与样本

  • 回顾性分析,纳入11例NPM1突变、MRD阳性、体能状态良好的急性髓系白血病患者,接受超说明书使用的维奈克拉联合阿扎胞苷作为移植桥接策略。
  • 治疗时9例为分子学复发,2例为分子学持续,均为MRD阳性完全缓解(CRMRDpos)。

主要发现

  • 接受中位2周期(范围1-4)维奈克拉联合阿扎胞苷后,9/11(81.8%)达到CRMRD阴性(CRMRDneg)。
  • 全部11例患者均接受HSCT,自治疗开始中位随访26个月,移植后中位随访19个月。
  • 10/11患者存活(1例死于非复发死亡),9/10患者处于MRD阴性状态。

临床怎么用

  • 作者认为,对于NPM1突变AML分子学失败患者,维奈克拉联合阿扎胞苷可作为移植桥接策略,以防止明显复发、实现深度缓解并保持移植前体能。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

NPM1-mutated acute myeloid leukaemia (NPM1mut AML) represents a mostly favourable/intermediate risk disease that benefits from allogeneic haematopoietic stem cell transplantation (HSCT) in case of measurable residual disease (MRD) relapse or persistence after induction chemotherapy. Although the negative prognostic role of pre-HSCT MRD is established, no recommendations are available for the management of peri-transplant molecular failure (MF). Based on the efficacy data of venetoclax (VEN)-based treatment in NPM1mut AML older patients, we retrospectively analysed the off-label combination of VEN plus azacitidine (AZA) as bridge-to-transplant strategy in 11 NPM1mut MRD-positive fit AML patients. Patients were in MRD-positive complete remission (CRMRDpos ) at the time of treatment: nine in molecular relapse and two in molecular persistence. After a median number of two cycles (range 1-4) of VEN-AZA, 9/11 (81.8%) achieved CRMRD -negative (CRMRDneg ). All 11 patients proceeded to HSCT. With a median follow-up from treatment start of 26 months, and a median post-HSCT follow-up of 19 months, 10/11 patients are alive (1 died from non-relapse mortality), and 9/10 patients are in MRDneg status. This patient series highlights the efficacy and safety of VEN-AZA to prevent overt relapse, achieve deep responses and preserve patient fitness before HSCT, in patients with NPM1mut AML in MF.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Sartor C, Brunetti L, Audisio E, et al. A venetoclax and azacitidine bridge-to-transplant strategy for NPM1-mutated acute myeloid leukaemia in molecular failure. Br J Haematol. 2023. PMID: 37226312. doi:10.1111/bjh.18887

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。